Compound Evidence File
#EC-2026-0324
Aromasin (Exemestane)
Filed under Oral Tablets. The bureau holds 136 laboratory returns for this compound from 49 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
49 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 6 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 5 | 10.0 | 9.9 | 10.0 | 13 Jan 2026 | 4 Jul 2026 |
| BachemCASE #VI-2026-0314 | A | 4 | 10.0 | 9.9 | 10.0 | 10 Nov 2025 | 9 Jul 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 4 | 10.0 | 10.0 | 10.0 | 2 Jan 2026 | 23 May 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 4 | 10.0 | 9.9 | 10.0 | 28 Dec 2025 | 26 Jul 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 4 | 10.0 | 9.9 | 10.0 | 6 Feb 2026 | 28 Jun 2026 |
| SinoPepCASE #VI-2026-0387 | A | 4 | 10.0 | 9.9 | 10.0 | 5 Feb 2026 | 17 Jul 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 3 | 10.0 | 10.0 | 10.0 | 24 Apr 2026 | 12 Jul 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 3 | 10.0 | 10.0 | 10.0 | 25 Feb 2026 | 15 Jul 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 3 | 10.0 | 10.0 | 10.0 | 1 Jun 2026 | 10 Jul 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 2 | 10.0 | 10.0 | 10.0 | 22 Jan 2026 | 4 Jun 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 2 | 10.0 | 10.0 | 10.0 | 12 Apr 2026 | 20 May 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 2 | 10.0 | 10.0 | 10.0 | 17 Jul 2026 | 8 Aug 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 2 | 10.0 | 10.0 | 10.0 | 5 May 2026 | 8 Jun 2026 |
| BfflinkCASE #VI-2026-0212 | X | 1 | 10.0 | 10.0 | 10.0 | 27 Feb 2025 | 27 Feb 2025 |
| Paradigm PeptideCASE #VI-2026-0759 | X | 1 | 10.0 | 10.0 | 10.0 | 24 Apr 2025 | 24 Apr 2025 |
| NextGen HealthCASE #VI-2026-0604 | X | 1 | 10.0 | 10.0 | 10.0 | 21 May 2025 | 21 May 2025 |
| HomopeptideCASE #VI-2026-0760 | A | 4 | 9.9 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 4 | 9.9 | 9.9 | 10.0 | 19 Dec 2025 | 1 May 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 4 | 9.9 | 9.9 | 9.9 | 24 Mar 2026 | 21 Jun 2026 |
| AsymchemCASE #VI-2026-0091 | A | 4 | 9.9 | 9.9 | 10.0 | 14 Jan 2026 | 9 Aug 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 3 | 9.9 | 9.9 | 10.0 | 8 Nov 2025 | 11 May 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 3 | 9.9 | 9.9 | 10.0 | 9 Mar 2026 | 23 Jul 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 2 | 9.9 | 9.9 | 10.0 | 26 May 2026 | 4 Jul 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 2 | 9.9 | 9.9 | 10.0 | 23 Feb 2026 | 20 May 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 2 | 9.9 | 9.9 | 10.0 | 10 May 2026 | 11 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 3 | 9.2 | 8.6 | 9.6 | 24 May 2026 | 24 May 2026 |
| Amino LairCASE #VI-2026-0413 | X | 1 | 9.2 | 9.2 | 9.2 | 16 Mar 2025 | 16 Mar 2025 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 8 | 8.8 | 7.3 | 10.0 | 24 May 2026 | 24 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 2 | 8.5 | 7.7 | 9.3 | 24 May 2026 | 24 May 2026 |
| AKS ChemCASE #VI-2026-0313 | X | 1 | 8.5 | 8.5 | 8.5 | 24 Apr 2025 | 24 Apr 2025 |
| Shandong Nuoweiou Medical Technology CoCASE #VI-2026-0076 | X | 1 | 8.3 | 8.3 | 8.3 | 9 Jun 2025 | 9 Jun 2025 |
| Peptide PartnersCASE #VI-2026-0295 | X | 2 | 8.2 | 7.0 | 9.5 | 16 Mar 2025 | 20 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 7 | 8.1 | 6.5 | 9.0 | 24 May 2026 | 24 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 4 | 8.0 | 7.5 | 8.9 | 24 May 2026 | 24 May 2026 |
| Verified PeptidesCASE #VI-2026-0407 | X | 3 | 7.1 | 3.5 | 9.2 | 27 Feb 2025 | 17 May 2026 |
| LiliPeptideCASE #VI-2026-0695 | X | 8 | 7.0 | 3.8 | 10.0 | 7 May 2025 | 25 May 2026 |
| Heman Peptide HMCASE #VI-2026-0089 | X | 1 | 6.8 | 6.8 | 6.8 | 20 Jun 2025 | 20 Jun 2025 |
| Amino AsylumCASE #VI-2026-0828 | X | 1 | 6.5 | 6.5 | 6.5 | 2 Jul 2025 | 2 Jul 2025 |
| Alpha-GenCASE #VI-2026-0905 | X | 2 | 6.4 | 5.2 | 7.6 | 11 Jun 2025 | 19 Jan 2026 |
| Shandong Aishi BiotechnologyCASE #VI-2026-0308 | X | 1 | 6.2 | 6.2 | 6.2 | 3 Jun 2025 | 3 Jun 2025 |
| EHZ PeptidesCASE #VI-2026-0296 | C | 3 | 6.1 | 4.7 | 7.9 | 8 Jul 2025 | 23 May 2026 |
| Alimo PeptideCASE #VI-2026-0524 | X | 1 | 5.8 | 5.8 | 5.8 | 7 May 2025 | 7 May 2025 |
| Bulk Peptide SupplyCASE #VI-2026-0446 | X | 2 | 5.5 | 4.4 | 6.5 | 21 May 2025 | 26 Jan 2026 |
| Coastal PeptidesCASE #VI-2026-0958 | X | 2 | 5.1 | 4.9 | 5.3 | 11 Jun 2025 | 24 May 2026 |
| Liberty PeptidesCASE #VI-2026-0416 | X | 1 | 4.3 | 4.3 | 4.3 | 27 Feb 2025 | 27 Feb 2025 |
| Changan District Sheng Peptide TradingCASE #VI-2026-0341 | X | 1 | 3.1 | 3.1 | 3.1 | 27 Feb 2025 | 27 Feb 2025 |
| SubQ SocietyCASE #VI-2026-0716 | X | 1 | 0.0 | 0.0 | 0.0 | 24 Apr 2025 | 24 Apr 2025 |
| Hebei Chengtong TechnologyCASE #VI-2026-0520 | X | 1 | 0.0 | 0.0 | 0.0 | 3 Jul 2025 | 3 Jul 2025 |
Open any subject to view the batch-level evidence for Aromasin (Exemestane) alone.